Table 1. The discrepancy rate between primary and metastatic lesions.
Cancer type | Biomarker type | Discrepancy rate, % | Concordance rate, % | Reference |
---|---|---|---|---|
Melanoma | BRAF | 13.40 | 86.60 | (8) |
Breast | ER | 17.80 | 82.20 | (9) |
PR | 45.40 | 54.60 | ||
HER2 | 13.30 | 86.70 | ||
Colon | KRAS | 8 | 92 | (10) |
BRAF | 8 | 92 | ||
PIK3CA | 7 | 93 | ||
Kidney | PD-1 | 27 | 73 | (11) |
PD-L1 | 22 | 78 | ||
Lung cancer | PD-L1 | 70 | 30 | (1) |
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; PD-L1, programmed death-ligand 1; PD-1, programmed death 1.